Procyon Financial Statements From 2010 to 2024
| PCYN Stock | USD 0.24 0.01 4.35% |
Check Procyon financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Procyon's main balance sheet or income statement drivers, such as , as well as many indicators such as . Procyon financial statements analysis is a perfect complement when working with Procyon Valuation or Volatility modules.
Procyon |
Procyon Company Return On Equity Analysis
Procyon's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Procyon Return On Equity | -0.0934 |
Most of Procyon's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Procyon is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Procyon has a Return On Equity of -0.0934. This is 99.61% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is 69.87% lower than that of the firm.
Procyon Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Procyon's current stock value. Our valuation model uses many indicators to compare Procyon value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Procyon competition to find correlations between indicators driving Procyon's intrinsic value. More Info.Procyon is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Procyon by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Procyon's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Procyon Financial Statements
Procyon investors utilize fundamental indicators, such as revenue or net income, to predict how Procyon Pink Sheet might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems in the United States. The company was incorporated in 1987 and is based in Oldsmar, Florida. Procyon Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 19 people.
Pair Trading with Procyon
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Procyon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Procyon will appreciate offsetting losses from the drop in the long position's value.Moving against Procyon Pink Sheet
The ability to find closely correlated positions to Procyon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Procyon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Procyon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Procyon to buy it.
The correlation of Procyon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Procyon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Procyon moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Procyon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Procyon Pink Sheet
Procyon financial ratios help investors to determine whether Procyon Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Procyon with respect to the benefits of owning Procyon security.